Phase I study of recombinant interleukin-15 in combination with checkpoint inhibitors nivolumab and ipilimumab in subjects with refractory cancers.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.tps3128
Abstract: TPS3128Background: Interleukin-15 is a stimulatory cytokine. Recombinant human IL-15 (rhIL-15), a nonglycosylated single-chain peptide, increased circulating CD8+T-cells, NK cells and inflammatory ... read more here.
Keywords: study recombinant; recombinant interleukin; checkpoint inhibitors; interleukin combination ... See more keywords